 Shares of Esperion Therapeutics Inc. ESPR, -1.72 were down 1.5 in premarket trading on Monday after the company said it plans to reduce its workforce by 40, citing the challenges of launching two cholesterol-lowering medications during the pandemic. It also said it plans to streamline its commercial strategy, and with those programs in place, Esperion expects to save at least 20 million in 2021. 